Expanding an Analytical Framework
Increased expectations, increased accountability
Rapid evolution. In short, that’s what we’re seeing in the method development and assay life cycle field. The concepts have been around for quite some time, but now with updated and new guidance for analytical life cycle and analytical method development, we’re seeing a more dynamic period emerging in the space. This includes increased expectations for analytical method development and increased accountability for reporting development data.
Looking back at 2022
Four events that made it a great year
I must admit, I’m a sucker for just about any list article. Show me a title such as, “8 Reasons Why…” or “10 Movies That…”, and there’s a pretty good chance I’ll click. I often find myself scrolling through the strangest lists, reviewing things that I really don’t care about – kitchen gadgets, closet organizing products, stocking stuffers. I’m hopeless. I’m compelled to click.
Fast Advances Highlight CRISPR 2.0
A focus on personalized therapeutics
Genomic medicine field has progressed in leaps and bounds these last few years, and at the 3rd Annual CRISPR 2.0 conference, it was wonderful to again connect in person with colleagues to discuss those advances. It was a great opportunity to listen and learn from a prestigious lineup of gene editing experts from across the industry.
Aiming for improved delivery, safety, at ESGCT
Covering multiple modalities
Every year, October marks the change in the season, the dropping of temperatures, and the height of conference season for biotech. This year’s ESGCT meeting in Edinburgh, Scotland, was the event’s first in-person occurrence since 2019, and it was exciting to be back – Edinburgh didn’t disappoint! There was rich dialogue amongst industry experts, healthy attendance with over 2,000 delegates, exceptional networking events, and the city of Edinburgh was a joy with several unseasonably sunny days.
Big topics not always on conference agendas
For events such as Biotech Week Boston, industry leaders, suppliers, regulatory agencies and academia come together to collaborate, present and partner on topics related to biotechnology, specifically therapeutics. And every year there is an unspoken theme you don’t see on the agenda, where speakers, attendees and sponsors discuss shared pain points, challenges and what the future could hold.
Novel Stem Cell Therapies
A first look at patient data at ISSCR
I’m always grateful for the chance to hear the latest results from drug developers in the CRISPR space. That’s why it was a huge bonus to have a world class cell and gene therapy conference just fifteen minutes down the road from Aldevron Madison in September!
BIO Convention Brings Optimism, Concerns
Timelines and Supply Chains Still Seen as Challenges
BIO International’s annual convention is one of the largest gatherings of biotechnology innovators in the world. The Aldevron team attending this year’s in-person gathering in San Diego observed that the past few years of COVID restrictions haven’t changed the high interest in our industry.
Connecting on CRISPR
Innovation from the CRISPR 2022 Meeting
When it comes to gene editing technology, there are few meetings as valuable for us and our collaborators as the annual CRISPR meeting. Academic in focus and highly technical in nature, the 2022 edition of this event came to Boston, packing more than 40 lectures and 120 posters into a rapid-fire, three-day learning experience.
Rare Disease and a Repeatable Process
Of all the presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, a presentation by renowned physician and geneticist Dr. Francis Collins caught our attention. In his talk, Dr. Collins spotlighted an encouraging path forward in the treatment of rare diseases with cell and gene therapies. While acknowledging that gene therapy is being taken to new heights in many areas, he noted there are still thousands of diseases that have not yet had a focus for treatment development.